Table 1.
Patient Characteristics
| Characteristic | n (%) |
|---|---|
| Total, N | 207 |
| Study type | |
| Externally peer-reviewed | 27 (13.0) |
| Industrial | 122 (58.9) |
| Institutional | 58 (28.0) |
| Age, median (range), y | 61 (31–91) |
| Sex | |
| Female | 99 (47.8) |
| Male | 108 (52.2) |
| Race | |
| Black/African American | 29 (14.0) |
| Other | 15 (7.2) |
| White | 163 (78.7) |
| Ethnicity | |
| Hispanic | 7 (3.4) |
| Non-Hispanic | 200 (96.6) |
| Cancer type | |
| Breast/Gynecologic | 23 (11.1) |
| Central nervous system | 14 (6.8) |
| Gastrointestinal | 78 (37.7) |
| Genitourinary | 33 (15.9) |
| Melanoma/Sarcoma | 28 (13.5) |
| Thoracic/Lung | 31 (15.0) |
| Referred from outside institution | |
| No | 121 (58.5) |
| Yes | 86 (41.5) |
| Treatments before study, median (range), n | 2 (0–9) |
| Referred to palliative care before progression (n=207) | 98 (47.3) |
| Goals of care documented (n=207) | 109 (52.7) |
| Hospice discussed after progression (n=207) | 84 (40.6) |
| Received other treatment after progression (n=206) | 109 (52.9) |
| Died (n=207) | 177 (85.5) |
| Died within 1 y of study enrollment (n=177) | 145 (81.9) |